Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320626 | 0.88 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DTUBB1 | |
| SCHEMBL4821217 | 0.83 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4821221 | 0.83 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8268703 | 0.83 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8268707 | 0.82 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8313341 | 0.82 | ALDH1A1 (0.53) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL13986032 | 0.80 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DTUBB1 | |
| SCHEMBL8269332 | 0.79 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8319800 | 0.77 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4818613 | 0.77 | MAPT (0.53) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470723-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION | 2008-05-15 | — | — | US | disclosed |
| US-7312241-B2 | Diphenylethylene compounds and uses thereof | CELGENE CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2004078144-A2 | DIPHENYLETHYLENE COMPOUNDS AND USES THEREOF | CELGENE CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114061-A1 | Diphenylethylene compounds and uses thereof | VHL, TNF, PTGES | PDE4A 2547/4885PDE4B 2484/4885PDE4C 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.